Chemotherapy-Induced Anemia

Pathophysiology, grading, and evidence-based management including ESA therapy, IV iron, and transfusion thresholds

Key Points

• Chemotherapy-induced anemia (CIA) affects 50–60% of patients receiving cytotoxic chemotherapy; cisplatin-based regimens cause the most severe and sustained anemia.
• Erythropoiesis-stimulating agents (ESAs) are only indicated when hemoglobin falls below 10 g/dL in patients receiving chemotherapy with non-curative intent — they are contraindicated in curative settings.
• IV iron supplementation improves ESA response and is now recommended even without overt iron deficiency (functional iron deficiency with transferrin saturation <20%).
• Red blood cell (RBC) transfusion is generally indicated at Hgb <7–8 g/dL or for symptomatic anemia at higher thresholds; patients with cardiovascular disease may require transfusion at Hgb <8–9 g/dL.
• ESAs increase thromboembolism risk by ~50–70% and are associated with reduced survival in some tumor types; informed consent and shared decision-making are mandatory before starting therapy.
• Fatigue is the most common and debilitating symptom of CIA; even moderate anemia (Hgb 10–12 g/dL) significantly impairs quality of life and functional capacity.

Definition, Incidence, and Clinical Impact

Anemia is defined as a hemoglobin (Hgb) level below the normal reference range: <13.0 g/dL in adult men and <12.0 g/dL in adult women (WHO criteria). In oncology, grading follows the NCI Common Terminology Criteria for Adverse Events (CTCAE v5.0): - **Grade 1:** Hgb <LLN (lower limit of normal) to 10.0 g/dL — mild - **Grade 2:** Hgb 8.0–10.0 g/dL — moderate; symptomatic, limiting instrumental ADLs - **Grade 3:** Hgb <8.0 g/dL — severe; transfusion indicated - **Grade 4:** Life-threatening; urgent intervention required Chemotherapy-induced anemia (CIA) affects approximately 50–60% of patients…

Pathophysiology and Contributing Factors

CIA is multifactorial. Understanding the specific contributing mechanisms guides treatment selection. **1. Direct bone marrow suppression:** Cytotoxic agents damage erythroid progenitor cells (BFU-E and CFU-E) in the bone marrow, reducing red blood cell production. The degree of marrow suppression depends on the agent, dose, and cumulative exposure. Unlike neutropenia, anemia develops more gradually (red cells have a 120-day lifespan) but is more persistent. **2. Cisplatin-mediated EPO suppression:** Cisplatin and, to a lesser extent, carboplatin cause direct renal tubular toxicity that…

Evaluation of CIA

A structured evaluation is essential before initiating treatment — the cause of anemia determines the appropriate intervention. **Initial workup:** - CBC with differential and reticulocyte count: low reticulocyte count (hypoproliferative pattern) suggests marrow suppression or EPO deficiency; high reticulocyte count with anemia suggests hemolysis or bleeding - Peripheral blood smear: evaluate red cell morphology (macrocytosis → B12/folate deficiency; schistocytes → MAHA/TMA; spherocytes → AIHA) - Iron studies: serum iron, total iron-binding capacity (TIBC), transferrin saturation (TSAT),…

Erythropoiesis-Stimulating Agents (ESAs) — Indications and Risks

ESAs (epoetin alfa, darbepoetin alfa) stimulate erythroid progenitor proliferation and differentiation, reducing transfusion requirements. Their use is tightly regulated by FDA labeling and ASCO/ASH guidelines due to documented safety concerns. **ASCO/ASH 2019 Guideline — ESA Indications (Evidence Grade 1A):** - Chemotherapy-associated anemia with Hgb 1 g/dL in any 2-week period (too-rapid rise increases thrombosis risk). **Major risks of ESA therapy:** - Venous thromboembolism: risk increased ~50–70% (HR ~1.6); DVT and PE are the most common serious adverse events - Hypertension: especially…

Iron Supplementation

Iron supplementation has emerged as a critical component of CIA management — both as monotherapy for true iron deficiency and as an adjunct to ESA therapy for functional iron deficiency. **IV iron is preferred over oral iron in the oncology setting** for several reasons: - Oral iron absorption is suppressed by elevated hepcidin (the inflammatory state of cancer) - Oral iron causes GI side effects (nausea, constipation, diarrhea) that are particularly burdensome in patients already experiencing chemotherapy-induced GI toxicity - IV iron bypasses the hepcidin block and rapidly replenishes both…

Red Blood Cell Transfusion

RBC transfusion provides the most rapid correction of symptomatic anemia and is the only option when immediate correction is required. However, transfusions carry risks and are not appropriate as routine management for mild-moderate CIA. **ASCO 2021 Transfusion Guideline Thresholds:** - **Hgb 10 g/dL:** transfusion is generally NOT indicated regardless of symptoms - **Hgb 8–10 g/dL without clear symptoms:** individualize based on performance status, rate of decline, upcoming surgery, and patient preferences **Transfusion strategy:** Typically 1–2 units of packed RBCs (pRBCs) per episode;…